Targeted Therapy for Sleep Apnoea: A Novel Personalised Approach

Obstructive sleep apnoea (OSA) is characterised by the recurrent collapse or narrowing of the upper airway during sleep. OSA is also associated with adverse cardiovascular, metabolic, neurocognitive, quality of life and safety consequences. The first line treatment continuous positive airway pressure (CPAP) which is highly efficacious but poorly tolerated. Oral mandibular advancement splint (MAS) therapy is the leading alternative to CPAP to treat obstructive sleep apnoea, although it is difficult to predict treatment success.

Therefore, this study aims to determine the efficacy of targeted therapeutic approaches to treat OSA whilst using novel techniques to advance knowledge of upper airway function and the mechanisms of a MAS device. We aim to develop accurate tools to predict treatment outcome with a MAS device, develop novel approaches to monitor and diagnose OSA. This study is a part of the government Cooperative Research Centre Program linking researchers and industry.

Health Areas

Expertise & facilities

Donate to us

Every dollar of community support enables our scientists to continue making life-changing discoveries that contribute to a brighter and healthier future.


Fundraise for us

Run, swim or bake your way to making a positive difference in the lives of people touched by brain and nervous system disorders.

Get involved